Media Inquiries

Meredith Kaya

Vice President, Investor Relations and Corporate Communications

617.374.5082

mkaya@ironwoodpharma.com

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

bcalitri@ironwoodpharma.com
Sort by Year
October 19, 2017

Ironwood Pharmaceuticals to Host Third Quarter 2017 Investor Update Call

October 16, 2017

Ironwood Pharmaceuticals Presenting Linaclotide Data at the World Congress of Gastroenterology at ACG 2017

September 6, 2017

Ironwood Pharmaceuticals Announces Leadership Change

August 31, 2017

Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

August 21, 2017

Ironwood Pharmaceuticals Announces FDA Approval of DUZALLO® (lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout

August 3, 2017

Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update

July 20, 2017

Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease

July 20, 2017

Ironwood Pharmaceuticals to Host Second Quarter 2017 Investor Update Call

June 8, 2017

Ironwood Pharmaceuticals to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

June 1, 2017

Ironwood Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 10, 2017

Ironwood Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference

May 9, 2017

Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide’s Effect on Pain at Digestive Disease Week® 2017

May 8, 2017

Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update

May 1, 2017

Ironwood Pharmaceuticals to Present New Data for Linaclotide, Linaclotide Delayed Release and IW-1701 at Digestive Disease Week® 2017

April 24, 2017

Ironwood Pharmaceuticals to Host First Quarter 2017 Investor Update Call

Copyright © 2020, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.